DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations - Yan, X; Lin, Z; Lifang, Z; Yingchun, W; Mei, W; Zhenfan, Y (Cancer Res, 2019)